



Open Government Impact Statement

81st Oregon Legislative Assembly
2021 Regular Session

Measure: SB 711 - B

Only impacts on Original or Engrossed
Versions are Considered Official

Prepared by: Cameron D. Miles
Date: 6/2/2021

SUMMARY

Requires Department of Consumer and Business Services to study cost differences in hormone replacement drugs used by men and hormone replacement drugs used by women and report findings to Legislative Assembly no later than September 15, 2022. Requires department to keep strictly confidential information submitted in accordance with prescription drug price transparency program that is collected, used or relied upon for study, if information is not already in public domain and is confidential, proprietary or trade secret.

Sunset January 2, 2023.

Takes effect on 91st day following adjournment sine die.

OPEN GOVERNMENT IMPACT

Legislative Counsel has not adopted standards for drafting measures that establish exemptions from disclosure of public records.

This measure prohibits public disclosure by the Department of Consumer and Business Services of information submitted in accordance with the prescription drug transparency program that is collected, used or relied upon for a study related to cost differences between hormone replacement drugs used by men and those used by women, if the information is not already in the public domain and is confidential, proprietary or a trade secret.

If those public records that could be subject to public disclosure were instead subject to mandatory disclosure under public records law, confidential, proprietary or trade secret information submitted by drug manufacturers under the prescription drug transparency program would more likely be made public.